Publications by authors named "Ray El Boustany"

Claim this Profile
G
Genetic variants of interferon-response factor 5 are associated with the incidence of chronic kidney disease: the D.E.S.I.R. study.
Frédéric Fumeron, Gilberto Velho, Fawaz Alzaid, Ray El Boustany, Claire Vandiedonck

Genes Immun· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma total adiponectin and changes in renal function in a cohort from the community: the prospective Data from an Epidemiological Study on the Insulin Resistance Syndrome study.
Frédéric Fumeron, Ray El Boustany, Jean-Philippe Bastard, Soraya Fellahi, Beverley Balkau

Nephrol Dial Transplant· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Apelin and Risk of Type 2 Diabetes in a Cohort From the Community.
Isabelle Castan-Laurell, Ray El Boustany, Ophélie Pereira, Louis Potier, Michel Marre

Diabetes Care· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes.
Louis Potier, Ronan Roussel, Michel Marre, Petter Bjornstad, David Z Cherney, Ray El Boustany

Diabetes Care· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vasopressin and Diabetic Kidney Disease.
Ray El Boustany

Ann Nutr Metab· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.
Gilberto Velho, Stéphanie Ragot, Ray El Boustany, Pierre-Jean Saulnier, Mathilde Fraty

Cardiovasc Diabetol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population.
Ray El Boustany, Irina Tasevska, Esther Meijer, Lyanne M Kieneker, Sofia Enhörning

JCI Insight· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes.
Ray El Boustany, Christopher Taveau, Catherine Chollet, Gilberto Velho, Lise Bankir

J Diabetes Complications· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[2016 Two-day doctoral conference organised by the Doctoral school "physiology, physiopathology and therapeutics" Pierre and Marie Curie University, Paris].
Sami Ayari, Cécile Bandet, Marion Dajon, Ray El Boustany, Sara Ghezzal

Med Sci (Paris)· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes.
Gilberto Velho, Ray El Boustany, Guillaume Lefèvre, Kamel Mohammedi, Frédéric Fumeron

Diabetes Care· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study.
Ronan Roussel, Nadia Matallah, Nadine Bouby, Ray El Boustany, Louis Potier

Am J Nephrol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community.
Ronan Roussel, Ray El Boustany, Nadine Bouby, Louis Potier, Frédéric Fumeron

J Clin Endocrinol Metab· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis